Cargando…
Diabetes Drugs and Cardiovascular Safety
Diabetes is a well-known risk factor of cardiovascular morbidity and mortality, and the beneficial effect of improved glycemic control on cardiovascular complications has been well established. However, the rosiglitazone experience aroused awareness of potential cardiovascular risk associated with d...
Autor principal: | Bae, Ji Cheol |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Endocrine Society
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4923407/ https://www.ncbi.nlm.nih.gov/pubmed/27302713 http://dx.doi.org/10.3803/EnM.2016.31.2.239 |
Ejemplares similares
-
Cardiovascular outcomes and safety with antidiabetic drugs
por: Aldossari, Khaled K.
Publicado: (2018) -
Assessment of Cardiovascular Safety of Anti-Osteoporosis Drugs
por: Fuggle, N. R., et al.
Publicado: (2020) -
Cardiovascular Safety Assessment in Cancer Drug Development
por: Oren, Ohad, et al.
Publicado: (2021) -
Cardiovascular safety of non-insulin pharmacotherapy for type 2 diabetes
por: Xu, James, et al.
Publicado: (2017) -
Effectiveness and Safety of Fufang Danshen Dripping Pill (Cardiotonic Pill) on Blood Viscosity and Hemorheological Factors for Cardiovascular Event Prevention in Patients with Type 2 Diabetes Mellitus: Systematic Review and Meta-Analysis
por: Wi, Minji, et al.
Publicado: (2023)